Evgen Pharma PLC Grant of Options (5963O)

TIDMEVG

RNS Number : 5963O

Evgen Pharma PLC

30 January 2019

For immediate release 30 January 2019

Evgen Pharma plc

("Evgen" or the "Company")

Grant of Options

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that, on 28 January 2019, certain employees of the Company including the following Persons Discharging Managerial Responsibility ("PDMR") were granted nil cost options over a total of 826,743 ordinary shares in the Company exercisable, subject to the option vesting, for a period of up to ten years from the date of grant under the Evgen Pharma plc Long Term Incentive Plan ("LTIP").

 
 PDMR                   Position                   Options granted 
 Dr Stephen Franklin    Chief Executive Officer            471,061 
                       -------------------------  ---------------- 
 Richard Moulson        Chief Financial Officer            155,682 
                       -------------------------  ---------------- 
                        Clinical Development 
 Sally Ross              Officer                           200,000 
                       -------------------------  ---------------- 
 

The number of nil cost options awarded has been calculated by reference to the three month weighted average share price to 28 January 2018.

These nil cost options are subject to the rules of the LTIP. The options will vest on the third anniversary of grant subject to a minimum absolute total shareholder return (TSR) from the grant date to the vesting date of 10%, at which 25% of the awards will vest, and then on a straight line basis to a 20% TSR at which 100% of the awards will vest. Re-testing of this performance condition after the vesting date is not permitted.

Enquiries:

 
 Evgen Pharma plc                                c/o [phone] 
  Dr Stephen Franklin, CEO 
  Richard Moulson, CFO 
  www.evgen.com 
 finnCap 
  Geoff Nash, Teddy Whiley (Corporate 
  Finance) 
  Alice Lane, Manasa Patil (ECM) 
  www.finncap.com                                    [phone] 
 WG Partners LLP 
  Nigel Barnes, Claes Spång                     [phone] 
 Buchanan 
  Mark Court, Sophie Wills, Tilly 
  Abraham 
  [e-mail]                              [phone] 
 

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
1    Details of the person discharging managerial responsibilities/person closely associated 
a)   Name                                                           Steve Franklin 
2    Reason for the notification 
a)   Position/status                                                Chief Executive 
b)   Initial notification /Amendment                                Initial Notification 
3    Details of the issuer, emission allowance market participant, auction platform, auctioneer 
      or auction monitor 
a)   Name                                                           Evgen Pharma Plc 
b)   Legal Entity Identifier                                        213800NO3E6TSTQO8K20 
4    Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
      each type of transaction; (iii) each date; and (iv) each place where transactions have been 
      conducted 
a)   Description of the financial instrument, type of instrument    Options over ordinary shares of 0.25 pence each 
                                                                     GB00BSWYN304 
      Identification code 
b)   Nature of the transaction                                      Grant of options 
c)   Currency                                                       GBP 
d)   Price(s) and volume(s)                                         Price(s)                   Volume(s) 
  nil                                                                                          471,061 
 
e)   Aggregated information 
      - Aggregated volume 
      - Price 
      - Aggregated total 
f)   Date of the transaction                                        28 January 2019 
g)   Place of the transaction                                       London Stock Exchange, AIM 
 
 
1    Details of the person discharging managerial responsibilities/person closely associated 
a)   Name                                                           Richard Moulson 
2    Reason for the notification 
a)   Position/status                                                Chief Financial Officer 
b)   Initial notification /Amendment                                Initial Notification 
3    Details of the issuer, emission allowance market participant, auction platform, auctioneer 
      or auction monitor 
a)   Name                                                           Evgen Pharma plc 
b)   Legal Entity Identifier                                        213800NO3E6TSTQO8K20 
4    Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
      each type of transaction; (iii) each date; and (iv) each place where transactions have been 
      conducted 
a)   Description of the financial instrument, type of instrument    Options over ordinary shares of 0.25 pence each 
 
      Identification code                                            GB00BSWYN304 
b)   Nature of the transaction                                      Grant of options 
c)   Currency                                                       GBP 
d)   Price(s) and volume(s)                                         Price(s)                   Volume(s) 
  nil                                                                                          155,682 
 
e)   Aggregated information 
      - Aggregated volume 
      - Price 
      - Aggregated total 
f)   Date of the transaction                                        28 January 2019 
g)   Place of the transaction                                       London Stock Exchange, AIM 
 
 
1    Details of the person discharging managerial responsibilities/person closely associated 
a)   Name                                                           Sally Ross 
2    Reason for the notification 
a)   Position/status                                                Clinical Development Officer 
b)   Initial notification /Amendment                                Initial Notification 
3    Details of the issuer, emission allowance market participant, auction platform, auctioneer 
      or auction monitor 
a)   Name                                                           Evgen Pharma plc 
b)   Legal Entity Identifier                                        213800NO3E6TSTQO8K20 
4    Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
      each type of transaction; (iii) each date; and (iv) each place where transactions have been 
      conducted 
a)   Description of the financial instrument, type of instrument    Options over ordinary shares of 0.25 pence each 
 
      Identification code                                            GB00BSWYN304 
b)   Nature of the transaction                                      Grant of options 
c)   Currency                                                       GBP 
d)   Price(s) and volume(s)                                         Price(s)                   Volume(s) 
  nil                                                                                           200,000 
 
e)   Aggregated information 
      - Aggregated volume 
      - Price 
      - Aggregated total 
f)   Date of the transaction                                        28 January 2019 
g)   Place of the transaction                                       London Stock Exchange, AIM 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHSDLFWSFUSEEF

(END) Dow Jones Newswires

January 30, 2019 12:28 ET (17:28 GMT)